Showing 2641-2650 of 5771 results for "".
- Vital Tears and Brightstar Therapeutics Form Joint Medical Advisory Boardhttps://modernod.com/news/vital-tears-and-brightstar-therapeutics-form-joint-medical-advisory-board/2486040/Vital Tears and Brightstar Therapeutics have announced the formation of a joint Medical Advisory Board, bringing together nine leaders in ophthalmology and optometry to help guide the organizations’ expanding clinical and scientific initiatives.
- FDA Officially Shifts to One-Trial Standard for New Drug Approvalshttps://modernod.com/news/fda-officially-shifts-to-one-trial-standard-for-new-drug-approvals/2485753/The FDA has announced a major change to its regulatory framework, formally establishing that a single well-designed pivotal clinical trial will be the new default basis for most drug and therapeutic approvals—replacing the long-standing expectation that two indepen
- Harrow Launches PharmaPack Direct-to-Prescriber Kits for Ophthalmic Medicationshttps://modernod.com/news/harrow-launches-pharmapack-direct-to-prescriber-kits-for-ophthalmic-medications/2485736/Harrow announced the launch of PharmaPack, a new Direct-to-Prescriber (DTP) cash-pay offering designed to expand access to affordable, FDA-approved branded ophthalmic medications. According to Harrow, by providing transparent,
- LKC Technologies, Provider of Visual Electroretinography, Acquired by AMETEKhttps://modernod.com/news/lkc-technologies-provider-of-visual-electroretinography-acquired-by-ametek/2485723/LKC Technologies announced it has been acquired by Ametek, a provider of industrial technology solutions. Financial terms of the deal were not disclosed. LKC Technologies is the maker of t
- iVeena Doses First Participant in Phase 1 Trial of IVMED-85 for Myopia Progressionhttps://modernod.com/news/iveena-doses-first-participant-in-phase-1-trial-of-ivmed-85-for-myopia-progression/2485668/iVeena Delivery Systems announced that the first patient has been dosed in its phase 1, first-in-human clinical study of IVMED-85 in healthy adult volunteers. The phase 1 trial is designed to evaluate the safety and tolerabili
- HOYA Presents New Data on MiYOSMART iQ Spectacle Lenseshttps://modernod.com/news/hoya-presents-new-data-on-miyosmart-iq-spectacle-lenses/2485625/HOYA Vision Care recently announced interim 6-month data from its randomized controlled clinical trial evaluating the safety and efficacy of MiYOSMART iQ spectacle lenses to treat children 4 to 12 years of age who have progressive myopia. The company’s myopia control solution uses the defocu
- China’s NMPA Approves Zeiss Artevo 750 and Artevo 850 Ophthalmic Microscopeshttps://modernod.com/news/chinas-nmpa-approves-zeiss-artevo-750-and-artevo-850-ophthalmic-microscopes/2485563/Zeiss announced that China’s National Medical Products Administration (NMPA) has approved the Zeiss Artevo 750 and Zeiss Artevo 850 ophthalmic microscopes. Designed to support both anterior and posterior segment procedures, th
- FDA Approves Yuvezzi, First Dual-Agent Eye Drop for Presbyopiahttps://modernod.com/news/fda-approves-yuvezzi-first-dual-agent-eye-drop-for-presbyopia/2485503/Tenpoint Therapeutics announced that the FDA has approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for the treatment of presbyopia in adults. Previously known as Brimochol PF, Yuvezzi is the first and only FDA-approved dual-agent
- Orasis Pharmaceuticals Presents New Data Showing Qlosi Is Pupil Selective in Presbyopic Eyeshttps://modernod.com/news/orasis-pharmaceuticals-presents-new-data-showing-qlosi-is-pupil-selective-in-presbyopic-eyes/2485470/Orasis Pharmaceuticals announced new clinical data demonstrating that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% is pupil selective, significantly reducing pupil diameter without a statistically significant change in ciliary muscle response in presb
- Nidek Introduces Phantom Open-field Refraction Systemhttps://modernod.com/news/nidek-introduces-phantom-open-field-refraction-system/2485460/Nidek announced the launch of the Phantom Open-field Refraction System. Phantom is an open-field binocular refraction system that eliminates the use of physical lenses entirely—placing nothing in front of the patient’s eyes. According to Nidek, by removing this lon